Cobra Signs Agreement with Advaxis to Manufacture Lovaxin C Vaccine

Keele, UK, 22 October 2007 - UK based Cobra Biomanufacturing Plc (AIM: CBF) has signed an agreement with North Brunswick, NJ based Advaxis (OTCBB: ADXS) to manufacture Phase II clinical trial material of a therapeutic cervical cancer vaccine known as Lovaxin C.

Commenting on the contract: David Thatcher, CEO at Cobra, said:

“We have been supporting the Advaxis Lovaxin C clinical program since 2003 and are delighted to extend our work with Advaxis on this exciting project.”

Commenting on the contract: John Rothman, Vice President, Clinical Development, said:

“We look forward to continuing our relationship with Cobra as we move forward with the development of live Listeria vaccines for the treatment of cancer. Our initial clinical work demonstrated the real world utility of our concepts, and Cobra’s ability to execute their production as potential cancer immunotherapeutic agents.”

-Ends-

For further information:

At Cobra Biomanufacturing:

Cobra Biomanufacturing Plc
David Thatcher, Chief Executive Officer
Tel: 44 (0) 1782 714 181

Buchanan Communications Tel: 44 (0) 207 466 5000
Tim Anderson/Mark Court/Rebecca Skye Dietrich

Northbank Communications (trade press enquiries)
Gemma Price Tel: 44 (0) 207 268 3240

At Advaxis:
Advaxis Inc Tel: 1 732 545 1590
Thomas A Moore ( moore@advaxis.com )

Investor Relations/Public Relations contact: Tel: 1 212 825 3210
Investors Relations Group
Antima (Taz) Sadhukhan

Media contact: Tel: 1 212 825 3210
Janet Vasquez, Public Relations

About Lovaxin C Vaccine
Based on over a decade of work in the laboratory of Dr. Yvonne Paterson at the University of Pennsylvania, the Company's broadly enabling Listeria technology platform uses modified Listeria monocytogenes to deliver a tumor-specific antigen fusion protein. Listeria has the ability to generate a robust immune response and produce an unusually strong and effective therapeutic immune response to existing cancers and other diseases affecting many related immune mechanisms simultaneously and in an integrated fashion. 'Advaxis’ Listeria-based technology not only generates an unusually profound cytotoxic immune response capable of killing cancer cells, but the Company’s proprietary antigen fusion protein technology minimizes the suppressive effects of regulatory T cells that appear to inhibit many vaccines, and also creates a local tumor environment conducive to the therapeutic effects of the activated tumor killing cells.

Unlike current products on the market, which are ineffective in women already infected with HPV, which causes cervical cancer, Lovaxin C is designed to treat women who have already developed cervical cancer as a result of the HPV infection.

About Cobra Biomanufacturing Plc
Cobra Biomanufacturing Plc is a leading international manufacturer of biopharmaceuticals to the lifescience industry. Founded in 1992, Cobra provides innovative manufacturing solutions to the biopharmaceutical industry covering DNA, virus, cellular therapeutics and recombinant protein products.

Cobra has developed a range of unique, patented technologies, which underpins a successful revenue generating contract manufacturing business.

Cobra floated on the Alternative Investment Market of the London Stock Exchange in June 2002 raising £7 million and raised a further £5.2 million in May 2003 in order to further expand capacity in Oxford UK. Since floatation the Company has grown turnover from £3 million to £10 million providing expert manufacturing services across the world with over 80% of revenues currently from the US market.

www.cobrabio.com

About Advaxis, Inc.
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chairperson of Advaxis' Scientific Advisory Board. Advaxis is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes multiple simultaneous immunological mechanisms to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

Statements contained within this press release may contain forward-looking comments which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as ‘may’, ‘will’, ‘could’, ‘forecasts’, ‘expects’, ‘plans’, ‘anticipates’, ‘believes’, ‘estimates’, ‘predicts’, ‘potential’, or ‘continue’. Predictions and forward-looking references in this press release are subject to the satisfactory progress of research, which is, by nature, unpredictable. Forward projections reflect management’s best estimates based on information available at the time of issue.